Press releases
- Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences
- Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia
- Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia
- Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma
- Arrowhead Pharmaceuticals Reports Fiscal 2024 Second Quarter Results
- Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma
- Arrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences
- Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars
- Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results
- Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease
More ▼
Key statistics
On Friday, Arrowhead Pharmaceuticals Inc (HDP1:MUN) closed at 21.16, 6.87% above its 52-week low of 19.80, set on Dec 01, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 21.16 |
---|---|
High | 21.16 |
Low | 21.16 |
Bid | 21.12 |
Offer | 21.22 |
Previous close | 21.16 |
Average volume | 20.60 |
---|---|
Shares outstanding | 124.20m |
Free float | 118.64m |
P/E (TTM) | -- |
Market cap | 2.85bn USD |
EPS (TTM) | -4.24 USD |
Data delayed at least 15 minutes, as of May 31 2024 07:04 BST.
More ▼